Aurobindo Pharma Ltd, a Hyderabad-based manufacturer of generic
pharmaceuticals and active pharmaceutical ingredients (APIs), has received
tentative approval for Lopinavir/Ritonavir tablets in 100/25mg and 200/50mg
from the US Food and Drug Administration (US FDA).

With this abbreviated new drug application (ANDA), which was reviewed under
the expedited provisions of the President’s Emergency Plan for AIDS Relief
(PEPFAR), the Hyderabad-based company now has 93 ANDA approvals from the
FDA, including 66 final approvals.

Lopinavir/Ritonavir tablets is the generic equivalent of Abbott
Laboratories’ Kaletra tablets and falls under the anti-retroviral (ARV)
segment, which is indicated in combination with other ARV agents for the
treatment of HIV-I infections in adults and children above the age of two
years. This is the first generic product tentatively approved under the
PEPFAR for Abbott’s Kaletra, Aurobindo stated in a press release on
Thursday.

B.Karthick

Research Analyst

WWW.KENCES1.BLOGSPOT.COM <http://www.kences1.blogspot.com/>

--~--~---------~--~----~------------~-------~--~----~
You received this message because you are subscribed to the Google Groups 
"Kences1" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to 
[email protected]
For more options, visit this group at 
http://groups.google.com/group/kences1?hl=en
-~----------~----~----~----~------~----~------~--~---

Reply via email to